Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS).
Waddell EN, Springer SA, Marsch LA, Farabee D, Schwartz RP, Nyaku A, Reeves R, Goldfeld K, McDonald RD, Malone M, Cheng A, Saunders EC, Monico L, Gryczynski J, Bell K, Harding K, Violette S, Groblewski T, Martin W, Talon K, Beckwith N, Suchocki A, Torralva R, Wisdom JP, Lee JD.
Waddell EN, et al. Among authors: wisdom jp.
J Subst Abuse Treat. 2021 Sep;128:108389. doi: 10.1016/j.jsat.2021.108389. Epub 2021 Apr 8.
J Subst Abuse Treat. 2021.
PMID: 33865691
Free PMC article.